Please enable Javascript
Localized Renal Cell Carcinoma
Advertisement
Comparing ctDNA, Conventional Imaging for Monitoring Patients With Localized RCC After Surgery
Zachary Bessette
Localized Renal Cell Carcinoma
|
April 27, 2025
A research analysis evaluated tumor-informed ctDNA analysis versus traditional imaging techniques for localized RCC.
Read More
Preoperative ctDNA Detectability Linked to Tumor Aggressiveness and Recurrence in Localized RCC
Brandon Twyford
Renal Cell Carcinoma Diagnostics
|
April 27, 2025
Pre-op ctDNA in localized RCC is linked to aggressive tumor features and worse RFS, highlighting its prognostic potential.
Read More
Histologic Subtype Not Linked to Cancer-Specific Survival After Robotic Partial Nephrectomy, Study Finds
Brandon Twyford
Renal Cell Carcinoma
|
April 26, 2025
Histologic subtype did not significantly affect 5-year cancer-specific survival after robotic partial nephrectomy for RCC.
Read More
PSMA-Guided MDT Shows Promise in Oligometastatic RCC
Emily Menendez
Renal Cell Carcinoma Diagnostics
|
March 4, 2025
A recent proof-of-concept study has further evaluated the efficacy of PSMA-guided MDT for oligometastatic RCC.
Read More
Robotic Surgery, Multidisciplinary Care for RCC
Jihad Kaouk, MD
Localized Renal Cell Carcinoma
|
January 21, 2025
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
View More
Surveillance Versus Surgery for Small Renal Masses
Jose A. Karam, MD, FACS
Localized Renal Cell Carcinoma
|
January 21, 2025
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
View More
Proteinuria Incidence After Radical Versus Partial Nephrectomy
Emily Menendez
Localized Renal Cell Carcinoma
|
January 8, 2025
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
Read More
Perioperative, Adjuvant Nivolumab Versus Surgery With Surveillance: RFS in High-Risk RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
July 8, 2024
The standard of care for intermediate to high-risk RCC consists of partial or radical nephrectomy and surveillance.
Read More
KIM-1 Biomarker Analysis in IMmotion010: Adjuvant Atezolizumab for RCC at High Recurrence Risk
Laurence Albiges, MD, PhD
Localized Renal Cell Carcinoma
|
June 10, 2024
Dr. Albiges breaks down a biomarker analysis of circulating kidney injury molecule-1 in the IMmotion010 trial.
View More
Preoperative Risk Calculator for Evaluating Nephron-Sparing Completion in Kidney Cancer
Katy Marshall
Localized Renal Cell Carcinoma
|
May 10, 2024
Researchers analyzed the connection between the outcomes and specific predictors of interest.
Read More
Effects of Positive Surgical Margin in RCC After Adjuvant, Neoadjuvant Therapy
Katy Marshall
Localized Renal Cell Carcinoma
|
May 3, 2024
Previous studies investigating adjuvant therapy in patients with RCC have not included those with PSM.
Read More
Predictors of Renal Function Improvement After Partial Nephrectomy
Jonathan Afari, MD
Localized Renal Cell Carcinoma
|
April 24, 2024
Dr. Afari elaborates on the factors he identified that contribute to renal function improvement post-partial nephrectomy.
View More
Predicting Renal Function Improvement After Partial Nephrectomy
Zachary Bessette
Localized Renal Cell Carcinoma
|
April 8, 2024
Dr. Afari and colleagues sought to better understand factors leading to renal function improvement after partial nephrectomy.
Read More
SABR Offers Acceptable Side Effect Profile, Efficacy for Primary RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
March 28, 2024
For patients with primary RCC who are ineligible for surgical resection, SABR serves as a viable alternative.
Read More
SABR Provides Novel Alternative to Surgical Resection for Primary RCC
Emily Menendez
Localized Renal Cell Carcinoma
|
March 8, 2024
FASTRACK II was the first trial of its kind to examine nonsurgical definitive therapy in patients with primary RCC.
Read More
Transperitoneal Nephrectomy Offers Better Tumor Recurrence Than Retroperitoneal Procedure
Emily Menendez
Localized Renal Cell Carcinoma
|
February 15, 2024
While RLRN and TLRN procedures were found to have similar efficacy, TLRN also resulted in better surgical specimen integrity.
Read More
CheckMate 914 Part B: Nivolumab Monotherapy for Localized RCC After Nephrectomy
Viktor Grünwald, MD, PhD
ASCO GU Symposium 2024
|
January 30, 2024
Dr. Grünwald describes the CheckMate 914 Part B analysis and investigating adjuvant nivo for patients with localized RCC.
View More
KEYNOTE-564: OS Results From Adjuvant Pembrolizumab for Clear Cell RCC
Zachary Bessette
ASCO GU Symposium 2024
|
January 27, 2024
After 57 months of follow-up, adjuvant pembro demonstrates improvement in OS in patients with ccRCC at risk of recurrence.
Read More
CheckMate 914: Adjuvant Nivolumab Monotherapy for Patients With Localized RCC
Katy Marshall
ASCO GU Symposium 2024
|
January 30, 2024
The study's second phase analyzed data from patients with RCC scheduled to undergo radical or partial nephrectomy.
Read More
Targeted Gene Panel Testing Can Assist Patients With RCC, Germline Mutations
Emily Menendez
Localized Renal Cell Carcinoma
|
March 11, 2024
Targeted gene panel testing can serve as an option for patients if syndromic features are present.
Read More
Load More
Advertisement
Advertisement